The 2021 Annual Meeting on Fibromuscular Dysplasia is being held in Cleveland, Ohio on October 16th, 2021. We are hopeful of having an in person meeting. Stay tuned for more details.
Each year we gather the leading specialists to come and speak about FMD. This is one of the most beneficial meetings anyone interested in learning more about FMD can attend. During the meeting you will learn about the most recent developments in FMD management along with hearing specialist discuss their most recent understandings of the disease.
Not only will you hear from specialists, but you will also be able to speak with them directly in open panel discussions. These open panel discussions give you the opportunity to ask specialists anything that may not have been answered during the presentations.
You will also have the opportunity to meet others with FMD. If you or a loved one has FMD, it can be hard for others to understand things you may be dealing with in relation to the disease. Being able to connect with others who can relate, can help with your ability to cope with FMD by know you're not the only one and others may provide you with their tips and trick for dealing with certain issues (always consult with your physician prior to applying any of the recommendations).
The meeting is Saturday October 16th in Cleveland, Ohio (8am-4pm) and there will be a meet and greet the evening of Friday October 15th.
Both events take place at the Crown Plaza Hotel in downtown Cleveland, Ohio ( 216-615-7500 mention FMDSA).
- What is Fibromuscular Dysplasia?
- Treatment of Cervical Artery Dissection and Intracranial Aneurysms
- Identifying the Patient Likely to Benefit from Renal Artery Angioplasty
- Pulsatile Tinnitus and Current Treatment Options
- Spontaneous Coronary Artery Dissection: treatment, exercise and the iSCAD Registry
- FMD and SCAD research update
- United States FMD Registry: what has it taught us?
- Dr Jeffrey Olin - Mt Sinai, New York
- Dr Heather Gornik - University Hospital, Cleveland, Ohio
- Dr Santhi Ganesh - University of Michigan
- Dr Shazam Hussain - Cleveland Clinic, Cleveland, Ohio
(We are still finalizing speakers and topics...stay tuned!) Event speakers and details are subject to change.
The Second International Symposium, "Revisiting Fibromuscular Dysplasia & Related Vascular Diseases."
Here is a video from this years international symposium:
Texas Tech University Health Sciences Center El Paso
We are excited to announce that Texas Tech University Health Sciences Center El Paso Department of Neurology is now participating in the FMD registry. They are a multidisciplinary group composed by physicians from the Department of Neurology, Cardiology, Nephrology, and Radiology serving a large US-Mexico Borderline Community of West Texas & Southern New Mexico. Their main goal is to increase recognition and awareness of FMD in Hispanic population and contribute to potential unique aspect of FMD in this particular Ethnic Group. If you would like to be seen by one of our physicians please make an appointment by contacting Dr. Alberto Maud, M.D. at firstname.lastname@example.org or to the program coordinator Israel Alba, MBA, CCRP at Israel.email@example.com or 915-215-4616.
The International Symposium, "Revisiting Fibromuscular Dysplasia & Related Vascular Diseases."
International collaborative efforts are underway to unravel the genetics, pathophysiology and natural history of FMD. The symposium was held in Feb of 2018 at the Belgium Royal Academy of Medicine, in Brussels. Hosted by C0-Presidents Prof. Alexandre Persu, Brussels Belgium and Prof. Heather Gornik, United States of America. To view the final program, click here.
Dr. Kambiz Zorriasateyn of NorthShore University Health System is a specialist in the areas of FMD and SCAD and would love to see you! (Not yet part of the USFMD Registry)
To find out more click on one of the following links!
Emory Healthcare Fibromuscular Dysplasia Symposium
The 2nd International FMD Research Network and SCAD Symposium 2017
The 2nd International FMD Research Network and SCAD Symposium took place in Cleveland, Ohio on May 18th-19th. The meeting was co-chaired by Dr. Heather Gornik, Dr. Jeffrey Olin and Dr. Esther Kim. FMDSA was very excited and proud to be a sponsor of the symposium which was very well attended.
Over 100 clinicians and researchers worldwide from the United States, Canada and Europe came together to discuss and update the state of the clinical science, scientific strategic planning and have in person conversation and collaboration in regard to FMD.
Four working groups were created, and a working group charge was identified for each group.
The groups and charge included:
1) Genetics/Reassessing the FMD Phenotype.
Working group charge: To consider the implications of broadening definitions used for assessment of the "FMD phenotype" and to discuss incorporation of patients with cervical artery dissection and SCAD into ongoing genetic research collaboration.
2) Exercise and Activity After Spontaneous Coronary Artery Dissection.
Working group charge: To strategize methodology for development of an expert opinion consensus on post SCAD exercise and activity for medical professionals and patients.
3) Maximizing Collaboration of International Registries.
Working group charge: To discuss, identify and strategize opportunities for collaboration of the United Sates Registry for FMD and the European FMD Registry.
4) Patient Advocacy Working Group.
Working group charge: To identify the unmet needs of the US and international FMD and SCAD patients and to determine potential mechanisms to address these needs.
Stay tuned for an update!
FMDSA Annual Meeting Photos 2017
FMDSA is an Official Charity of the 2018 Cleveland Marathon
For updates, information and to register for the 2018 marathon, click here.
FMD Awareness: May is now officially recognized as Fibromuscular Dysplasia Month in the State of Ohio! Thanks to the efforts of Nan Baker, House Bill 434 passed into law designating the month.
This designation is a major accomplishment not only for all of you who fight to raise awareness for this disease, but everyone who struggles with FMD on a daily basis. Please contact Pam Mace to learn more about the process and how you can make this happen in your state. Pictured are Ohio State Representative, Nan Baker and Cliff Rosenberger (Ohio Speaker of the House)
1st International Fibromuscular Dysplasia Research Network Symposium - May 15th-16th, Cleveland, OH
This meeting gathered key researchers and clinical thought leaders in the field of FMD for a state-of-the-art review of the existing knowledge base and current research activities related to FMD in the United States and abroad. Topics covered ranged from advances in imaging and diagnosis to an evaluation of connective tissue findings in FMD patients. A large proportion of the meeting was focused on the creation of an FMD research network, comprised of four focused working groups on various aspects of FMD research (epidemiology, genetics, research registries, and imaging and clinical therapeutics). The meeting was a great success and plans were developed to continue research network symposia in the following years. To view all abstracts presented and learn more about the Symposium and working groups, click here.
Members of all Symposium Working Groups are shown above.
Fibromuscular Dysplasia (FMD) Registry in France
We seek partnership with patient organizations. To my knowledge however, there exists no FMD patient association in Europe. This is why I am keen to have contacts with patients who could be interested in a European FMD initiative and would eventually attend our forthcoming FMD meeting (November 8th in Paris).
Written by Pr. Pierre-François Plouin, June 2013
ARCADIA (Assessment of Renal and Cervical Artery DysplasIA) is a French registry designed to document phenotypic and genetic traits in patients with renal and/or cervical artery fibromuscular dysplasia (FMD). PROFILE (PROgression of FIbromuscular LEsions) is a cohort study evaluating the progression of FMD lesions. These studies are coordinated by the hypertension unit and the reference center for rare vascular diseases at Georges-Pompidou European Hospital located in Paris, France. (https://www.maladiesvasculairesrares.com).
The main objective is to create a National FMD registry to collect standardized information from consenting patients diagnosed with the condition in 16 participating centers. The first application is the assessment of the frequency of multi-site FMD, i.e. the frequency of cervical artery FMD in patients presenting with renal artery FMD and vice-versa (ARCADIA and PROFILE). The second application is the assessment of the incidence and risk factors for progression of FMD lesions (PROFILE). The third application is case-control study to identify susceptibility genes for FMD, including genes that may influence disease progression or be associated with complications.
Patients are eligible if (a) they have renal or cervical artery FMD with either the string-of-beads sign (‘medial’ or multifocal FMD) or focal/tubular lesions (focal FMD) at CT-angiography, MR-angiography, or intra-arterial angiography; (b) they give informed consent to provide leukocyte DNA for analysis and for the collection of pertinent bio-clinical and morphologic annotations. In addition to DNA sampling and collection of cross-sectional information, patients who are available and willing to undergo a 3-year follow-up are offered the possibility to enroll in the PROFILE cohort. Phenotypic assessment, follow-up and indications for revascularization comply with current recommendations and best clinical practice. Patient participation lasts one day for ARCADIA, and 3 years for PROFILE.
The natural history of the condition will be better characterized, allowing development of optimal strategies for investigating, monitoring, following-up and treating patients with FMD. The biological and genetic study should help improve understanding of the pathophysiology and genetic determinism of this rare disease and open new possibilities for therapy.
International Collaborations -
FMDSA has earned the GuideStar Exchange Seal, demonstrating its commitment to transparency.
Patients United 2017
It is that time of year again when we are looking forward to our spring fundraiser "Patients United"
To date we have had 10 States participate in this event. Our hope is to one day have all 50 States Participate! The event is held during the months of March, April and May.
Individuals can have an event or groups can work on one together. Events have been large in size
or small. Whatever the member/members decide. Some past events have been
Wine Tasting Party
Napa Cottage Stay
Jeans Day at Work
Raffle a FMDSA Bracelet
First Giving Fundraising Page
As you can see there are lots of ways to fundraise. There are also many great fundraising ideas to be found on the internet. Small or big every dollar raised for FMDSA helps us to continue to support the FMD Registry funded solely by FMDSA.
If you are a group leader or member of a FMDSA support group perhaps your group might want to jointly work on a fundraiser. Or if you are an individual member and have not yet met others with FMD this might be a great way to reach out to someone and work on a fundraiser together.
Should you like to participate in Patients United or have any questions please contact Maureen Womack at firstname.lastname@example.org. Let's make this the most successful Fundraising year yet!
People Have the Power. "Fibromuscular Dysplasia Complications" 2016
Written by doctors Joshua Beckman and Mark Creager. The article was published in the Journal of the American College of Cardiology. Doctors Beckman and Creager use our patient registry as an excellent example of the collaboration between patients and physicians. "In our opinion, this model provides important opportunities to acquire new information and enhance understanding of poorly appreciated diseases."
"Dr. Seuss once wrote, "Unless someone like you cares a whole awful lot, nothing is going to get better. It's not". This article focuses on the success of FMDSA and our motivated patient group. Authored by, Kuck, Heidt, Kline-Rogers and published in the E. International Journal of Cardiology. 2016;208:95-96